866-997-4948(US-Canada Toll Free)

Global Dengue Vaccine Market 2017-2021

Published By :

Technavio

Published Date : Nov 2017

Category :

Infectious Disease

No. of Pages : 78 Pages

About Dengue Vaccine

The Aedes aegypti mosquito is responsible for transmitting the dengue virus (DENV). The virus that causes dengue belongs to the Flavivirus genus of the Flaviviridae family. Dengue fever resembles influenza and affects adults, children, as well as infants, but it is rarely fatal. However, dengue hemorrhagic fever is a potentially fatal complication because of multiple factors such as fluid accumulation, severe bleeding, organ impairment, or plasma leaking. The scientific community hypothesizes that the DENV evolved in nonhuman primates from where it spread to humans first in Southeast Asia and Africa and then to other parts of the world.

Technavios analysts forecast the global dengue vaccine market to grow at a CAGR of 15.05% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global dengue vaccine market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Dengue Vaccine Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
GlaxoSmithKline
Merck Sharp & Dohme
Sanofi
Takeda Pharmaceuticals

Other prominent vendors
GeneOne Life Sciences
Medigen Biologics
Panacea Biotec
Sun Pharmaceutical

Market driver
Rapid growth in disease prevalence
For a full, detailed list, view our report

Market challenge
Regulatory hurdles in vaccine penetration
For a full, detailed list, view our report

Market trend
Licensing deals
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2021 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
PART 03: RESEARCH METHODOLOGY
PART 04: INTRODUCTION
Market outline
PART 05: MARKET LANDSCAPE
Market overview
Market size and forecast
PART 06: FIVE FORCES ANALYSIS
PART 07: PIPELINE ANALYSIS
PART 08: MARKET SEGMENTATION BY END-USER
Government institutions
Hospitals
NGOs
PART 09: MARKET SEGMENTATION BY VACCINE TYPE
Live attenuated vaccines
Inactivated vaccines
PART 10: REGIONAL LANDSCAPE
Regional comparison
Dengue vaccine market in Americas
Dengue vaccine market in EMEA
Dengue vaccine market in APAC
Market opportunity
PART 11: DECISION FRAMEWORK
PART 12: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 13: MARKET TRENDS
Licensing deals
Growing awareness
Advances in diagnostic techniques
Novel approach to eliminate dengue
PART 14: VENDOR LANDSCAPE
PART 15: KEY VENDOR ANALYSIS
GlaxoSmithKline
Merck Sharp & Dohme
Sanofi Pasteur
Takeda Pharmaceuticals
Other prominent vendors
PART 16: APPENDIX
List of abbreviations
List of Exhibits
Exhibit 01: Forms of dengue
Exhibit 02: Transmission cycle of dengue infection
Exhibit 03: Global dengue vaccine market: Snapshot
Exhibit 04: Global dengue vaccine market: Segmentation
Exhibit 05: Global dengue vaccine market 2016-2021 ($ millions)
Exhibit 06: Global dengue vaccine market: Opportunity analysis
Exhibit 07: Five forces analysis
Exhibit 08: Pipeline landscape by development phase
Exhibit 09: Key clinical trials
Exhibit 10: Global dengue vaccine market share by end-user 2016
Exhibit 11: Global dengue vaccine market share by end-user 2021
Exhibit 12: Global dengue vaccine market by government institutions 2016-2021 ($ millions)
Exhibit 13: Global dengue vaccine market by hospitals 2016-2021 ($ millions)
Exhibit 14: Global dengue vaccine market by NGOs 2016-2021 ($ millions)
Exhibit 15: Types of dengue vaccine
Exhibit 16: Licensing of TV003 and TV005 by NIAID
Exhibit 17: Global dengue vaccine market by region 2016-2021
Exhibit 18: Regional comparison
Exhibit 19: Dengue vaccine market in Americas 2016-2021 ($ millions)
Exhibit 20: Dengue vaccine market in Americas: Year over year growth
Exhibit 21: Dengue vaccine market in EMEA 2016-2021 ($ millions)
Exhibit 22: Dengue vaccine market in EMEA: Year over year growth
Exhibit 23: Dengue vaccine market in APAC 2016-2021 ($ millions)
Exhibit 24: Dengue vaccine market in APAC: Year over year growth
Exhibit 25: Vaccines in global dengue vaccine market
Exhibit 26: GlaxoSmithKline: Key highlights
Exhibit 27: GlaxoSmithKline: Strength assessment
Exhibit 28: GlaxoSmithKline: Strategy assessment
Exhibit 29: GlaxoSmithKline: Opportunity assessment
Exhibit 30: Merck Sharp & Dohme: Key highlights
Exhibit 31: Merck Sharp & Dohme: Strength assessment
Exhibit 32: Merck Sharp & Dohme: Strategy assessment
Exhibit 33: Merck Sharp & Dohme: Opportunity assessment
Exhibit 34: Sanofi Pasteur: Key highlights
Exhibit 35: Sanofi Pasteur: Strength assessment
Exhibit 36: Sanofi Pasteur: Strategy assessment
Exhibit 37: Sanofi Pasteur: Opportunity assessment
Exhibit 38: Takeda Pharmaceuticals: Key highlights
Exhibit 39: Takeda Pharmaceuticals: Strength assessment
Exhibit 40: Takeda Pharmaceuticals: Strategy assessment
Exhibit 41: Takeda Pharmaceuticals: Opportunity assessment

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *